A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention

David Gregory, Dennis J. Scotti, Gregory de Lissovoy, Igor Palacios, Simon Dixon, Brijeshwar Maini, William O'Neill

Research output: Contribution to journalArticle

Abstract

Background: The economic burden of heart disease is heavy and growing. As advanced technologies for treating heart disease become available, decision makers need to be able to assess the relative value of such options against existing standards of care. Objectives: To compare the clinical and economic benefits of a percutaneous ventricular assist device (pVAD) versus an intra-aortic balloon pump (IABP) observed during the 90-day duration of the PROTECT II clinical trial, and to supplement these findings with a simulation of the longer-term value of this technology through the use of a Markov model to estimate the incremental cost-effectiveness of a pVAD relative to an IABP, in terms of quality-adjusted life-years (QALYs). Methods: Hospital bills were collected for patients enrolled in the PROTECT II trial who received hemodynamic support for high-risk percutaneous coronary intervention (PCI) provided by a pVAD (Impella 2.5) versus a conventional IABP during a 90-day episode of care (EOC). Length of stay, charges, and costs were analyzed for the index admissions, intensive care unit confinements, readmissions, and overall EOC. In addition, a probabilistic Markov model was used to project these parameters and their impact on a patient's quality of life for up to 10 years in relation to a pVAD versus an IABP. Results: Hospital costs for the index admission were lower for the IABP compared with the pVAD ($33,684 vs $47,667; P

Original languageEnglish (US)
JournalAmerican Health and Drug Benefits
Volume6
Issue number2
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Health Policy
  • Strategy and Management

Fingerprint Dive into the research topics of 'A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention'. Together they form a unique fingerprint.

  • Cite this